Teva Pharmaceutical Industries has acquired Labrys Biologics for US$200 M upfront plus up to US$625 M in pre-launch milestone payments. Labrys’ sole asset is LBR-101, a monoclonal antibody targeting CGRP (calcitonin gene-related peptide) that is in Phase IIb development for the prevention of chronic and high frequency episodic migraine and which the company acquired from Pfizer in 2012. The drug candidate is complementary to the single-use migraine patch Zecuity® (sumatriptan iontophoretic transdermal system), which Teva gained with its February 2014 purchase of NuPathe.